Forskning ved Københavns Universitet - Københavns Universitet

Forside

Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study. / Gustafsson, F; Køber, L; Torp-Pedersen, C; Per Hildebrandt.

I: Journal of Hypertension. Supplement, Bind 16, Nr. 1, 1998, s. S65-70.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Gustafsson, F, Køber, L, Torp-Pedersen, C & Per Hildebrandt 1998, 'Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study', Journal of Hypertension. Supplement, bind 16, nr. 1, s. S65-70.

APA

Gustafsson, F., Køber, L., Torp-Pedersen, C., & Per Hildebrandt (1998). Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study. Journal of Hypertension. Supplement, 16(1), S65-70.

Vancouver

Gustafsson F, Køber L, Torp-Pedersen C, Per Hildebrandt. Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study. Journal of Hypertension. Supplement. 1998;16(1):S65-70.

Author

Gustafsson, F ; Køber, L ; Torp-Pedersen, C ; Per Hildebrandt. / Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study. I: Journal of Hypertension. Supplement. 1998 ; Bind 16, Nr. 1. s. S65-70.

Bibtex

@article{6ef75b50123711df803f000ea68e967b,
title = "Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study",
abstract = "OBJECTIVE: To evaluate the influence of a history of arterial hypertension and the level of pretreatment blood pressure on the efficacy of the angiotensin converting enzyme (ACE) inhibitor trandolapril on mortality and morbidity in patients with acute myocardial infarction (AMI) and left ventricular dysfunction. METHODS: Data from the Trandolapril Cardiac Event study, in which 1749 patients with an enzyme verified AMI and echocardiographic evidence of left ventricular dysfunction were randomized in a double-blind manner to treatment with trandolapril or placebo, were retrospectively analysed. Follow up time was 24-50 months (mean 26 months). RESULTS: Four hundred patients (23{\%}) had a history of arterial hypertension. A total of 173 (43{\%}) patients with a history of hypertension died during follow up versus 500 (37{\%}) patients in the normotensive group. Treatment with trandolapril in the hypertensive individuals was associated with a reduction in the relative risk of death to 0.59 (95{\%} confidence interval 0.44-0.80), versus 0.85 (0.72-1.02) in the normotensive individuals. The significant reduction in mortality in hypertensive individuals persisted after multivariate analysis controlling for a broad spectrum of potential confounders. Also, benefit from ACE inhibition increased with increasing blood pressure at the time of randomization. Significant interactions between benefit from ACE inhibition and hypertension history, and systolic and diastolic blood pressure were found. CONCLUSION: ACE inhibition after AMI complicated by left ventricular dysfunction may be of particular importance in patients with a history of arterial hypertension or a relatively high pretreatment blood pressure. However, further investigations are necessary to establish the clinical impact of these results.",
author = "F Gustafsson and L K{\o}ber and C Torp-Pedersen and {Per Hildebrandt}",
note = "Keywords: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Indoles; Male; Medical Records; Myocardial Infarction; Ventricular Dysfunction, Left",
year = "1998",
language = "English",
volume = "16",
pages = "S65--70",
journal = "Journal of Hypertension. Supplement",
issn = "0952-1178",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study

AU - Gustafsson, F

AU - Køber, L

AU - Torp-Pedersen, C

AU - Per Hildebrandt, null

N1 - Keywords: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Indoles; Male; Medical Records; Myocardial Infarction; Ventricular Dysfunction, Left

PY - 1998

Y1 - 1998

N2 - OBJECTIVE: To evaluate the influence of a history of arterial hypertension and the level of pretreatment blood pressure on the efficacy of the angiotensin converting enzyme (ACE) inhibitor trandolapril on mortality and morbidity in patients with acute myocardial infarction (AMI) and left ventricular dysfunction. METHODS: Data from the Trandolapril Cardiac Event study, in which 1749 patients with an enzyme verified AMI and echocardiographic evidence of left ventricular dysfunction were randomized in a double-blind manner to treatment with trandolapril or placebo, were retrospectively analysed. Follow up time was 24-50 months (mean 26 months). RESULTS: Four hundred patients (23%) had a history of arterial hypertension. A total of 173 (43%) patients with a history of hypertension died during follow up versus 500 (37%) patients in the normotensive group. Treatment with trandolapril in the hypertensive individuals was associated with a reduction in the relative risk of death to 0.59 (95% confidence interval 0.44-0.80), versus 0.85 (0.72-1.02) in the normotensive individuals. The significant reduction in mortality in hypertensive individuals persisted after multivariate analysis controlling for a broad spectrum of potential confounders. Also, benefit from ACE inhibition increased with increasing blood pressure at the time of randomization. Significant interactions between benefit from ACE inhibition and hypertension history, and systolic and diastolic blood pressure were found. CONCLUSION: ACE inhibition after AMI complicated by left ventricular dysfunction may be of particular importance in patients with a history of arterial hypertension or a relatively high pretreatment blood pressure. However, further investigations are necessary to establish the clinical impact of these results.

AB - OBJECTIVE: To evaluate the influence of a history of arterial hypertension and the level of pretreatment blood pressure on the efficacy of the angiotensin converting enzyme (ACE) inhibitor trandolapril on mortality and morbidity in patients with acute myocardial infarction (AMI) and left ventricular dysfunction. METHODS: Data from the Trandolapril Cardiac Event study, in which 1749 patients with an enzyme verified AMI and echocardiographic evidence of left ventricular dysfunction were randomized in a double-blind manner to treatment with trandolapril or placebo, were retrospectively analysed. Follow up time was 24-50 months (mean 26 months). RESULTS: Four hundred patients (23%) had a history of arterial hypertension. A total of 173 (43%) patients with a history of hypertension died during follow up versus 500 (37%) patients in the normotensive group. Treatment with trandolapril in the hypertensive individuals was associated with a reduction in the relative risk of death to 0.59 (95% confidence interval 0.44-0.80), versus 0.85 (0.72-1.02) in the normotensive individuals. The significant reduction in mortality in hypertensive individuals persisted after multivariate analysis controlling for a broad spectrum of potential confounders. Also, benefit from ACE inhibition increased with increasing blood pressure at the time of randomization. Significant interactions between benefit from ACE inhibition and hypertension history, and systolic and diastolic blood pressure were found. CONCLUSION: ACE inhibition after AMI complicated by left ventricular dysfunction may be of particular importance in patients with a history of arterial hypertension or a relatively high pretreatment blood pressure. However, further investigations are necessary to establish the clinical impact of these results.

M3 - Journal article

C2 - 9534100

VL - 16

SP - S65-70

JO - Journal of Hypertension. Supplement

JF - Journal of Hypertension. Supplement

SN - 0952-1178

IS - 1

ER -

ID: 17422088